Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 7/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 11/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288825 | 0.95 | GABRA5 (0.56) | GABRA5GABRA1 | |
| SCHEMBL289169 | 0.85 | GABRA5 (0.49) | GABRA5GABRA1LMNANPC1RAB9A | |
| SCHEMBL289168 | 0.85 | GABRA5 (0.53) | GABRA5GABRA1 | |
| SCHEMBL287851 | 0.85 | GABRA5 (0.48) | GABRA5 | |
| SCHEMBL287914 | 0.84 | GABRA1 (0.47) | GABRA5GABRA1 | |
| SCHEMBL288243 | 0.84 | CNR1 (0.43) | GABRA5 | |
| SCHEMBL288078 | 0.84 | GABRA5 (0.54) | GABRA5GABRA1 | |
| SCHEMBL289018 | 0.82 | GABRA5 (0.44) | GABRA5GABRA1TSHR | |
| SCHEMBL287886 | 0.82 | GABRA5 (0.47) | GABRA5GABRA1 | |
| SCHEMBL535760 | 0.82 | GABRA5 (0.79) | GABRA5GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427456-B1 | ISOXAZOLE-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-02-05 | — | — | EP | claimed |
| EP-2427456-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | claimed |
| US-20100286132-A1 | PYRIDINES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | claimed |
| WO-2010127976-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | claimed |
| EP-2427456-B1 | ISOXAZOLE-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-02-05 | — | — | EP | disclosed |
| EP-2427456-B1 | ISOXAZOLE-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-02-05 | — | — | EP | disclosed |
| US-8415379-B2 | Pyridines | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415379-B2 | Pyridines | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415379-B2 | Pyridines | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2427456-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20100286132-A1 | PYRIDINES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286132-A1 | PYRIDINES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286132-A1 | PYRIDINES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| WO-2010127976-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010127976-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286132-A1 | PYRIDINES | GABRA5, CHRNA5, GABRA1 | GABRA5 1/4885GABRA1 3/4885LMNA 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.